<div id="readability-page-1"><p>LSV Asset Management grew its holdings in  GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 517.1% during the third quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 2,354,581 shares of the company's stock after purchasing an additional 1,973,017 shares during the period. LSV Asset Management owned about 0.68% of GoodRx worth $9,960,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p><ul><li>Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?</li></ul><p>Other institutional investors and hedge funds have also made changes to their positions in the company. Cetera Investment Advisers bought a new position in shares of  GoodRx in the second quarter worth about $50,000.  Walled Lake Planning &amp; Wealth Management LLC bought a new stake in  GoodRx during the 2nd quarter valued at about $55,000.  Tower Research Capital LLC TRC boosted its position in  GoodRx by 202.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company's stock valued at $56,000 after buying an additional 7,580 shares during the period.  Bayesian Capital Management LP bought a new position in  GoodRx in the 2nd quarter worth about $69,000.  Finally, Lazard Asset Management LLC grew its stake in  GoodRx by 43.6% in the 2nd quarter. Lazard Asset Management LLC now owns 17,142 shares of the company's stock worth $85,000 after acquiring an additional 5,201 shares in the last quarter. 63.77% of the stock is currently owned by institutional investors. </p><h2>GoodRx Stock Performance</h2><p>GDRX stock opened at $2.18 on Friday. The firm has a market cap of $739.96 million, a price-to-earnings ratio of 24.22, a PEG ratio of 0.83 and a beta of 1.50. The firm has a 50-day simple moving average of $2.61 and a two-hundred day simple moving average of $3.39. GoodRx Holdings, Inc. has a one year low of $2.10 and a one year high of $5.81. The company has a debt-to-equity ratio of 0.81, a quick ratio of 3.11 and a current ratio of 3.11. </p><h2>Analysts Set New Price Targets</h2><ul><li>This healthcare stock making a buzz with 160% growth</li></ul><p>Several analysts have recently weighed in on GDRX shares. Mizuho decreased their price target on shares of GoodRx from $5.00 to $4.00 and set a &#34;neutral&#34; rating for the company in a research note on Thursday, November 6th. JPMorgan Chase &amp; Co. reduced their price objective on GoodRx from $6.00 to $5.00 and set an &#34;overweight&#34; rating on the stock in a report on Tuesday, November 11th. Morgan Stanley decreased their target price on GoodRx from $5.00 to $4.00 and set an &#34;equal weight&#34; rating for the company in a research report on Thursday, December 18th. TD Cowen dropped their price target on GoodRx from $7.00 to $6.00 and set a &#34;buy&#34; rating on the stock in a research report on Monday, November 10th. Finally, Barclays initiated coverage on GoodRx in a research note on Monday, December 8th. They set an &#34;underweight&#34; rating and a $3.00 price target on the stock. Five research analysts have rated the stock with a Buy rating, seven have assigned  a Hold rating and three have issued  a Sell rating to the stock. Based on data from MarketBeat.com, GoodRx currently has a consensus rating of &#34;Hold&#34; and an average target price of $4.73.</p><p><b>Read Our Latest Stock Analysis on GDRX</b></p><h2>GoodRx Profile</h2> (Free Report)<ul><li>Gene therapy: Why does it cost millions for a single treatment? </li></ul><p>GoodRx Holdings, Inc <span>NASDAQ: GDRX<span></span></span> operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.  </p><p>In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than GoodRx</li><li>Your Bank Account Is No Longer Safe</li><li>Nvidia CEO Issues Bold Tesla Call</li><li>Buy this Gold Stock Before May 2026</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>The day the gold market broke</li></ul><p><strong>Want to see what other hedge funds are holding GDRX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0RSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0RSWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in GoodRx Right Now?</h2><p>Before you consider GoodRx, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.</p><p>While GoodRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

GDRX

<p>LSV Asset Management increased its stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 517.1% in Q3, owning 2,354,581 shares valued at approximately $9.96 million. Other institutional investors also adjusted their positions, with 63.77% of the stock held by institutions. GoodRx's stock opened at $2.18, with a market cap of $739.96 million. Analysts have set varied price targets, with a consensus rating of "Hold" and an average target price of $4.73. GoodRx operates a digital healthcare platform for comparing prescription drug prices.</p>

Market Beat

LSV Asset Management Boosts Stock Position in GoodRx Holdings, Inc. $GDRX